{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=17&state=Kentucky", "query": { "state": "Kentucky", "city": "Lexington", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 4513, "total_pages": 452, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=18&state=Kentucky&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=16&state=Kentucky&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T10:06:11.926Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006388", "title": "Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2000-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-10-20T10:06:11.926Z", "location_count": 237, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006388" }, { "nct_id": "NCT06064461", "title": "Vitaccess Real MG Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myasthenia Gravis" ], "interventions": [], "intervention_types": [], "sponsor": "Vitaccess Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2024-07-31", "completion_date": "2034-07", "has_results": false, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-10-20T10:06:11.926Z", "location_count": 6, "location_summary": "Orange, California • O'Fallon, Illinois • Lexington, Kentucky + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "O'Fallon", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Lumberton", "state": "New Jersey" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06064461" }, { "nct_id": "NCT01394952", "title": "Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Disease", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Dulaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 9901, "start_date": "2011-07-22", "completion_date": "2018-08-21", "has_results": true, "last_update_posted_date": "2019-10-08", "last_synced_at": "2026-10-20T10:06:11.926Z", "location_count": 51, "location_summary": "Mobile, Alabama • Pell City, Alabama • Phoenix, Arizona + 48 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01394952" }, { "nct_id": "NCT04458909", "title": "Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Nasopharyngeal Carcinoma", "Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Metastatic Nasopharyngeal Nonkeratinizing Carcinoma", "Metastatic Nasopharyngeal Undifferentiated Carcinoma", "Nasopharyngeal Nonkeratinizing Carcinoma", "Recurrent Nasopharyngeal Carcinoma", "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Recurrent Nasopharyngeal Undifferentiated Carcinoma", "Stage IV Nasopharyngeal Carcinoma AJCC v8", "Stage IVA Nasopharyngeal Carcinoma AJCC v8", "Stage IVB Nasopharyngeal Carcinoma AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2020-12-09", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-20T10:06:11.926Z", "location_count": 322, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 204 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04458909" }, { "nct_id": "NCT04105699", "title": "Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Sepsis" ], "interventions": [ { "name": "Blood sampling", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abionic SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 544, "start_date": "2019-12-10", "completion_date": "2023-12-28", "has_results": false, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-20T10:06:11.926Z", "location_count": 5, "location_summary": "Chicago, Illinois • Lexington, Kentucky • Toledo, Ohio + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Toledo", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04105699" }, { "nct_id": "NCT01897532", "title": "Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Linagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6991, "start_date": "2013-07-10", "completion_date": "2018-01-18", "has_results": true, "last_update_posted_date": "2019-04-04", "last_synced_at": "2026-10-20T10:06:11.926Z", "location_count": 197, "location_summary": "Huntsville, Alabama • Scottsboro, Alabama • Tuscumbia, Alabama + 150 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsboro", "state": "Alabama" }, { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01897532" }, { "nct_id": "NCT03021187", "title": "Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "semaglutide", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 731, "start_date": "2017-02-02", "completion_date": "2018-08-22", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-10-20T10:06:11.926Z", "location_count": 50, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Fountain Hills, Arizona + 44 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Hills", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03021187" }, { "nct_id": "NCT00873093", "title": "Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Childhood Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Lymphoblastic Lymphoma", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "L-asparaginase", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "High Dose MTX", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "31 Years", "sex": "ALL", "summary": "1 Year to 31 Years" }, "enrollment_count": 148, "start_date": "2009-03", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-01-27", "last_synced_at": "2026-10-20T10:06:11.926Z", "location_count": 157, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 124 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00873093" }, { "nct_id": "NCT00847821", "title": "Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Postmenopause" ], "interventions": [ { "name": "Bazedoxifene 10 mg/CE 0.625 mg", "type": "DRUG" }, { "name": "Bazedoxifene 20 mg/CE 0.625 mg", "type": "DRUG" }, { "name": "Bazedoxifene 40 mg/CE 0.625 mg", "type": "DRUG" }, { "name": "Bazedoxifene 10 mg/CE 0.45 mg", "type": "DRUG" }, { "name": "Bazedoxifene 20 mg/CE 0.45 mg", "type": "DRUG" }, { "name": "Bazedoxifene 40 mg/CE 0.45 mg", "type": "DRUG" }, { "name": "Raloxifene 60 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "40 Years to 75 Years · Female only" }, "enrollment_count": 185, "start_date": "2009-05", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2010-09-06", "last_synced_at": "2026-10-20T10:06:11.926Z", "location_count": 22, "location_summary": "Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00847821" }, { "nct_id": "NCT02153632", "title": "Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson's Disease", "Levodopa Induced Dyskinesia (LID)" ], "interventions": [ { "name": "amantadine HCl ER", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adamas Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 135, "start_date": "2014-07-30", "completion_date": "2016-05-20", "has_results": true, "last_update_posted_date": "2022-02-16", "last_synced_at": "2026-10-20T10:06:11.926Z", "location_count": 24, "location_summary": "Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02153632" } ] }